Microbial and Biochemical Pharmacy
Department：National Center for Screening Novel Microbial Drugs, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College
Education & Research Experience
2018/08 – 2019/08 Visiting Scholar under the State Scholarship Fund, Henry Ford Hospital Immunology program
2016/09 – Now Associate Professor, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences
2009/09 – 2016/09 Assistant Professor, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences
2006/09 – 2009/07 Ph.D. in Microbial and Biochemical Pharmacy, Peking Union Medical College
2003/09 – 2006/07 M.S. in Molecular Biology , Capital Normal University
1999/09 – 2003/07 B.S. in Biology of Science, Hebei Normal University
Discovery of antiviral or antitumor drugs and research on their mechanism
Dr. Zhang’s research has been focused on establishing high throughput screening (HTS) models for identifying lead compounds which have anti-viral or anti-tumor activities. The main content include: 1) establishment of HTS models targeting proteins of virus or tumor in vitro; 2) identification of lead compounds which have anti-viral or anti-tumor activities via HTS; 3) research on the molecular mechanism of the lead compounds and structural modification.
Dr. Zhang has gotten research support such as National Natural Science Foundation of China, CAMS Fundamental Research Funds, and so on.
1. Li Y#, Zhu X#, Zhang J, Lin Y, You X, Chen M, Wang Y, Zhu N*, Si S*. Identification of a Compound That Inhibits the Growth of Gram-Negative Bacteria by Blocking BamA-BamD Interaction. Front Microbiol. 2020，Jun 19;11:1252.
2. Yunyu Chen1#, Jing Zhang1#, Dongsheng Li1, Jiandong Jiang1, Yanchang Wang2, Shuyi Si1.Identification of a Novel Polo-like Kinase 1 Inhibitor that Specifically Blocks Polo-Box Domain-Mediated Protein-Protein Interactions. Oncotarget. 2017,8(1):1234-1246.
3. Han X#, Zhang J#, Guo L, Cao R, Li Y, Li N, Ma Q, Wu J*, Wang Y*, Si S*. A series of beta-carboline derivatives inhibit the kinase activity of PLKs. PLoS one,7(10):e46546. Epub 2012 Oct 3.
4.Yuan Lina,1, Yan Lia,1, Yuanjun Zhua,c, Jing Zhanga, Yongzhen Lia, Xiao Liua,Chunling Xiaoa, Bin Honga, Jiandong Jianga,2, Yanchang Wangb,2, Shuyi Sia,2. Identification of anti-tuberculosis agents that target ribosome subunit interaction using yeast two-hybrid system. Proc Natl Acad Sci U S A, 2012 Oct 23;109(43):17412-17417.
5. Jing Zhang#, Yan Li#, Liang Guo, Rihui Cao, Pei Zhao, Wei Jiang, Qin Ma, Hong Yi, Zhuorong Li, Jiandong Jiang, Jialin Wu*, Yanchang Wang*, Shuyi Si*. DH166, a beta-carboline derivative, inhibits the kinase activity of PLK1. Cancer Biol Ther,2009,8(24): 2374-2383.
Youth committee of Division of anti-inflammatory and immunological pharmacology，Chinese Pharmacological Society